CollPlant Expands the Distribution of its VergenixSTR Product in Europe

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) has announced the expansion of its European distribution network for Vergenix™ STR through a new agreement in Poland. The product, based on CollPlant's rhCollagen technology, is designed to treat various tendinopathies by combining with platelet-rich plasma (PRP) to form a scaffold that promotes tendon healing.

Vergenix™ STR targets multiple indications including tennis elbow, rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs. The product creates a gel matrix that enables localized, sustained release of growth factors at injury sites. CollPlant expects to deliver the first shipment to its Polish distributor by the end of 2025.

Positive

• Expansion into new European market through Polish distribution agreement
• Product addresses multiple tendon injury indications
• Strategic partnership with Allergan (AbbVie) for dermal and soft tissue fillers exists since 2021

Negative

• Company has a history of significant losses as mentioned in risk factors
• Requires additional capital raising which may not be obtained on acceptable terms

News Market Reaction – CLGN

+0.38%

1 alert

+0.38% News Effect

On the day this news was published, CLGN gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

REHOVOT, Israel, Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its European distribution network for Vergenix^™ STR through the signing of a new agreement in Poland. Vergenix^™STR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons.

Vergenix^™ STR is a soft tissue repair matrix specifically designed for combination with platelet-rich plasma (PRP). Upon mixing, it forms a scaffold with delayed degradation and strong retention at the injury site, supporting a localized and sustained therapeutic effect. The product is intended to promote tendon healing across multiple indications, including lateral epicondylitis ('tennis elbow'), rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs.  

Yehiel Tal, Chief Executive Officer of CollPlant, commented: "As we expand our distribution network across Europe and the Asia-Pacific region, we are excited about the significant market potential for Vergenix^™ STR. The product provides a differentiated treatment for tendon injuries by forming a gel matrix that enables localized, sustained release of growth factors at the injury site, thereby supporting optimal healing. We expect to deliver the first shipment to our distributor by the end of this year and look forward to further broadening our global distribution network for Vergenix^™ STR in additional territories."

About Vergenix STR

VergenixSTR is a soft tissue repair matrix that combines cross-linked rhCollagen with Platelet-rich plasma, or PRP, a concentrated blood plasma that contains high levels of platelets, a critical component of the healing process. Platelets contain growth factors that are responsible for stimulating tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation of the wound healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product is injected into the affected area and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon injury site, holding the platelet concentrate in place at the injured area. The matrix formed has the capabilities to activate the platelets in PRP, thereby releasing growth factors in a controlled manner and controlled biodegradation time, enabling optimal healing.

About CollPlant Biotechnologies

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com

Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future such as expectations regarding the market potential of VergenixSTR. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results, including with respect to the Company's dermal filler product; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers and the ability to manufacture and supply its products to cover market demands; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com

Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com

Photo: https://mma.prnewswire.com/media/2772688/COLLPLANT_VergenixSTR.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-expands-the-distribution-of-its-vergenixstr-product-in-europe-302556086.html

SOURCE CollPlant

FAQ

What is CollPlant's VergenixSTR and how does it work?

VergenixSTR is a soft tissue repair matrix that combines CollPlant's rhCollagen with platelet-rich plasma (PRP). It forms a gel matrix that acts as a scaffold, enabling controlled release of growth factors to promote tendon healing.

Which conditions can CollPlant's VergenixSTR treat?

VergenixSTR treats multiple tendon conditions including lateral epicondylitis (tennis elbow), rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs.

When will CollPlant (NASDAQ:CLGN) begin distribution of VergenixSTR in Poland?

CollPlant expects to deliver the first shipment to its Polish distributor by the end of 2025.

What is CollPlant's partnership with Allergan about?

CollPlant entered into a development and global commercialization agreement with Allergan (AbbVie) in 2021 specifically for dermal and soft tissue fillers.

How is CollPlant's VergenixSTR different from other tendon treatments?

VergenixSTR provides a differentiated treatment by forming a unique gel matrix that enables localized, sustained release of growth factors at the injury site, with controlled biodegradation time for optimal healing.